Estimated Acquisition Cost Differences between Fixed and Simulated Body Weight-Based Nivolumab Dosing Using Real-World Claims Data in Japan. (PubMed, Drugs Real World Outcomes) - Sep 18, 2026 - "Using real-world Japanese claims data and official drug prices, this study estimated higher acquisition costs based on observed fixed-dose quantities than those calculated for a simulated body-weight-based counterfactual at the index administration. The body-weight-based comparator was simulated for the same patients and did not represent an observed treatment group."
Journal • Real-world evidence
|
|
Ai Ohnishi; Rikuto Masuda; Tomoaki Yoshimura; Tomohiko Harada; Tomoya Sugimoto; Yoshihiro Noguchi
|